April 21, 2016
ChikVax Project Approval
CALIXAR and partners Awarded 3-Year Program for developing new vaccine against Chikungunya
CALIXAR is proud to announce the approval of the ChikVax project co-submitted with its partners CILOA and INSERM within the framework of the French Inter-Ministry Fund and with the support of the Eurobiomed cluster (eurobiomed.org).
The ChikVax project is intended to develop a new generation of vaccines based on the efficiency and synergy of native membrane antigens produced by and with the joint expertise of CALIXAR and CILOA.
The first vaccine prototype to be developed by the 3 partners will be directed against the Chikungunya virus.
After validation of the combined approaches’ potential, this process will then be applied to further viral proteins involved in other pandemic or endemic diseases including but not limited to HIV, Coronavirus (SARS and MERS), Ebola, Dengue, West Nile, Zika, etc.
Calixar, develops new approaches to isolate in solution – with the highest purity levels – full-length membrane antigens and proteins (GPCRs, Ion Channels, Transporters, Receptors and Viral Proteins), while keeping their structural and functional integrity (calixar.com).
Ciloa’s patented technology achieves production of native membrane proteins on natural microvesicles with high yield and stability. These exosomes can be used in a wide range of assays for receptor-ligand studies or injected to animals to develop monoclonal antibodies or vaccines (ciloa.com).
The Biology of Infection Unit has a proven experience on the Chikungunya Virus. Its work includes structural and functional studies of virus entry into host cells, deciphering virus cell biology by high-throughput screening, virus and the central nervous system infection.